Nanotechnology Can Detect 5-10 Bacteria per ml.

Biophage Pharma, a biopharmaceutical company engaged in the development of new therapeutics and clinical diagnostics based on its leading expertise in immunology and phage therapy, have announced that it has reached a significant milestone in the detection and quantification of bacteria.

The continued development of the Nanosensor has enabled Biophage to detect 5 to 10 bacteria in 1 ml of liquid sample. By allowing the detection of very small number of bacteria in a short period of time, this Nanosensor technology will be a valuable tool for environmental monitoring and biodefense.

"I am very pleased to announce that our recent results represent a breakthrough in the quantification of bacteria in a liquid sample," stated Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma Inc. "Based on innovations in Impedance Spectroscopy and Nanotechnology, our platform consists of a simple, label-free technique that requires very little sample manipulation. This technology can also be used to study cell toxicity and for high throughput screening," pursued Dr. Mandeville. The technology is being co-developed by Biophage and the Biotech Research Institute - CNRC (BRI) of Quebec.